Horizon Licenses Harvard Gene Editing IP | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery announced today that it has licensed non-exclusive rights to Harvard University's intellectual property covering gene-editing technology.

The Cambridge, UK-based firm said the license covers the commercialization of products that utilize Harvard's CRISPR gene-editing technology for research use. CRISPR is an RNA-guided gene editing system that can introduce either a targeted double strand break or single strand nick in the genome of mammalian cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.